Dengke Bao | Tumor biology | Best Researcher Award

Published on by China Scientist

Prof. Dr. Dengke Bao | Tumor biology | Best Researcher Award 

Dengke Bao, Ph.D., is a professor, Ph.D. supervisor, and Deputy Dean at the School of Pharmacy, Henan University. He is a recipient of the Excellent Youth Fund Project of the Henan Natural Science Foundation and the 2022 China Postdoctoral Science Foundation Funding. His research focuses on mitochondria-related mechanisms in tumorigenesis, cancer progression, and immune regulation. He has published 20+ SCI-indexed papers in top journals like Oncogene and Cell Death & Disease and serves as an editorial member for Scientific Reports. His work provides new insights into tumor microenvironment remodeling and drug resistance in cancer therapy.

Prof. Dr. Dengke Bao | Henan University | China

Profile

SCOPUS ID

ORCID ID

🎓Education

  • Dengke Bao holds a Ph.D. and has established himself as a distinguished professor and Ph.D. supervisor. His academic journey has been marked by excellence, leading to his recognition as a Program for Central Plains Youth Top Talent and a recipient of multiple prestigious research grants.

👨‍🏫Experience

  • Currently serving as the Deputy Dean of the School of Pharmacy at Henan University, Dengke Bao has played a pivotal role in advancing molecular diagnostics and therapy. He is also the Deputy Director of the Henan Engineering Research Center for Molecular Diagnosis and Therapy of Esophageal Cancer and the Director of the Laboratory of Biomarkers and Liquid Biopsy in Kaifeng. His work has significantly contributed to understanding mitochondria-related mechanisms in tumorigenesis, cancer progression, and tumor immune regulation.

🏆Awards and Recognitions

  • Dengke Bao has been honored with numerous awards, including the Excellent Youth Fund Project of the Henan Natural Science Foundation and recognition as a Young Core Instructor of Henan. He was also a recipient of the 2022 China Postdoctoral Science Foundation Funding, highlighting his exceptional contributions to the field of oncology research.

💡Skills and Certifications

  • With a deep expertise in tumor biology and the tumor microenvironment, Dengke Bao specializes in investigating mitochondrial damage-associated molecular patterns (DAMPs) and their role in inflammatory responses and cancer therapy resistance. His research combines molecular biology, oncology, and immunology to uncover new therapeutic strategies for hepatocellular carcinoma (HCC) and other malignancies.

🔬 Research Focus

  • Dengke Bao’s research is centered on understanding how mitochondrial damage-associated molecular patterns influence the tumor microenvironment and immune regulation. His groundbreaking study demonstrated that sorafenib treatment in HCC induces the release of mitochondrial DNA into the tumor microenvironment, promoting M2 macrophage polarization through TLR9 activation and enhancing sorafenib resistance. His findings offer a new perspective on targeting mitochondrial DAMPs to reprogram tumor-associated macrophages, providing novel strategies to improve therapeutic efficacy and overcome drug resistance in cancer treatment.

 📚 Publications and Editorial Roles

  • Dengke Bao has authored over 20 SCI-indexed papers as a first or corresponding author in high-impact journals, including Oncogene, Journal of Experimental & Clinical Cancer Research, and Cell Death & Disease. He also serves as an editorial member for Scientific Reports, further solidifying his influence in the field of cancer research.

🌎Conclusion

  • Given his exceptional research contributions, leadership, and impact in oncology, Dengke Bao is a highly suitable nominee for the Research for Best Researcher Award. His work is not only innovative but also holds great promise for improving cancer treatment and patient outcomes, making him a deserving recipient of this prestigious recognition.

📖Publications

  • TEFM facilitates uterine corpus endometrial carcinoma progression by activating ROS-NFκB pathway

    • Authors: J. Lei, Q. Zhu, J. Guo, D. Bao, R. Guo
    • Journal: Journal of Translational Medicine, 2024

  • Tenofovir disoproxil fumarate mediates neuronal injury by inducing neurotoxicity

    • Authors: X. Yang, J. Zhang, Y. Cheng, H. Liu, D. Bao
    • Journal: European Journal of Clinical Microbiology and Infectious Diseases, 2023

  • PRRSV infection activates NLRP3 inflammasome through inducing cytosolic mitochondrial DNA stress

    • Authors: H. Li, X. Yang, Y. Song, B. Wan, D. Bao
    • Journal: Veterinary Microbiology, 2023

Yuan Ma | Aptamer Drug | Best Researcher Award

Published on by China Scientist

Dr. Yuan Ma | Aptamer Drug | Best Researcher Award

Dr. Yuan Ma is a Research Assistant Professor at the Hong Kong Baptist University’s School of Chinese Medicine. He holds a PhD in Pharmaceutical Sciences from Peking University, specializing in nucleic acid chemistry and drug delivery systems. His research focuses on aptamer-based translational medicine and drug discovery, with applications in cancer and bone diseases. Dr. Ma has authored over 30 publications in high-impact journals and has been recognized with awards such as the 2024 Young Scientist Award. He combines expertise in organic chemistry, pharmacology, and teaching to advance innovative therapeutic solutions.

Dr. Yuan Ma | Hong Kong Baptist University | China

Profile

SCOPUS ID

ORCID ID

🎓 Education

  • Yuan Ma completed a Bachelor of Science degree in Pharmaceutical Sciences at Peking University in 2013, majoring in Organic Chemistry, Pharmacology, and Pharmaceutical Analysis. He pursued his Master of Science degree at the same institution, focusing on DNA Synthesis, Advanced Medicinal Chemistry, and Tumor Pharmacology, culminating in 2015. In 2019, Yuan earned a Doctor of Philosophy from the Stake Key Laboratory of Natural and Biomimetic Drugs at Peking University, specializing in Nucleic Acid Chemistry, Advanced Organic Chemistry, and Natural Pharmaceutical Chemistry. Her thesis explored novel nucleoside lipid delivery mechanisms.

💼 Experience

  • Dr. Yuan Ma is currently a Research Assistant Professor at the Institute for Advancing Translational Medicine in Bone & Joint Diseases and the School of Chinese Medicine, Hong Kong Baptist University, since 2022. His previous roles include Postdoctoral Research Fellow at the same institution and Associate Research Fellow at Mengchao Hepatobiliary Hospital of Fujian Medical University. He has contributed extensively to translational research in aptamer-based drug discovery and nucleic acid-based diagnostics.

 🏆 Honors and Awards

  • Yuan has received numerous accolades, including the 2024 Young Scientist Award at the 10th International Research Awards on Genetics and Genomics of Diseases in Paris, France. He was also named Peking University Outstanding Graduate in 2019 and received the Peking University Medical Student Special Scholarship in 2017.

🛠️ Skills and Certifications

  • Dr. Yuan possesses a strong command of nucleic acid chemistry, aptamer-based drug discovery, tumor pharmacology, and advanced organic synthesis. He is also proficient in teaching and mentoring, with extensive experience lecturing at undergraduate and postgraduate levels.

🔬 Research Focus

  • Yuan Ma’s research centers on aptamer-based translational research and drug discovery, emphasizing the development of targeted therapies for cancer and bone diseases. He has advanced methodologies in nucleic acid drug development, exploring innovative strategies for improved metabolic stability, binding affinity, and therapeutic efficacy.

Conclusion

  • Dr. Yuan Ma’s work exemplifies the spirit of innovation and dedication necessary for the Best Researcher Award. His contributions to aptamer-based drug discovery and nucleic acid chemistry have not only expanded the scientific understanding of targeted therapies but also paved the way for next-generation treatments in oncology and bone health. Given his academic accomplishments, ongoing research, and the potential for significant medical breakthroughs, He is undoubtedly a leading contender for this prestigious award

📄Publications

  • Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity
    Authors: Zhong, C., Li, N., Wang, S., … Liu, J., Zhang, G.
    Journal: Nature Communications, 2024, 15(1).
  • Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release
    Authors: Ma, Y., Xie, D., Chen, Z., … Lu, A., Zhang, G.
    Journal: Journal of Translational Medicine, 2024, 22(1).
  • Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics
    Authors: Amu, G., Zhang, G., Jing, N., Ma, Y.
    Journal: Journal of Medicinal Chemistry, 2024, 67(21).
  • Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy
    Authors: Ma, Y., Zhang, H., Shen, X., … Tang, T., Zhang, G.
    Journal: Cancer Letters, 2024, 598.
  • Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives
    Authors: Xiaohui, T., Wang, L., Yang, X., … Zhang, Z., Zhang, G.
    Journal: Journal of Orthopaedic Translation, 2024, 47.